Pulmonary Hypertension in Infants with Congenital Heart Defects: Are Leukotrienes Involved?
Author Information
Author(s): A. Serraf, J-P. Gascard, J. Bruniaux, C. Labat, C. Planche, C. Brink
Primary Institution: Service de Chirurgie et Réanimation Cardiaques Pédiatriques, CNRS ERS 566, Centre Chirurgical Marie-Lannelongue
Hypothesis
Are leukotrienes involved in pulmonary hypertension in infants with congenital heart defects?
Conclusion
The study found no correlation between pulmonary arterial pressure and leukotriene E4 levels in infants with pulmonary hypertension.
Supporting Evidence
- Leukotriene E4 levels were similar in infants with and without pulmonary hypertension.
- There was considerable variation in leukotriene E4 levels among patients.
- None of the patients received medication that could interfere with the arachidonic acid cascade.
Takeaway
The study looked at babies with heart problems to see if a substance called leukotriene E4 was related to high blood pressure in their lungs, but it found no link.
Methodology
Eighteen infants with congenital heart defects were studied, measuring leukotriene E4 levels in blood samples during surgery.
Limitations
The study had a small sample size and did not perform statistical analysis due to the limited number of patients.
Participant Demographics
Infants aged 2 to 25 months with congenital heart defects.
Want to read the original?
Access the complete publication on the publisher's website